Data Characteristics for This Category
Solid tumor product data comes from diverse sources. These include clinical trial reports, drug prescribing information, academic journal articles, conference abstracts, and internal pharmaceutical R&D documents. Document update frequencies vary. Clinical trial data is typically released in phases as trials progress. Drug prescribing information may be revised based on regulatory requirements or post-market surveillance. Most documents follow standard medical paper or report formats, including sections like abstract, introduction, methods, results, and discussion. Key fields include drug name, indications, mechanism of action, clinical efficacy data (e.g., Objective Response Rate ORR, Progression-Free Survival PFS, Overall Survival OS), adverse event rates, dosage and regimen, concomitant medications, and specific biomarker information. Efficacy data is often presented as percentages, medians, or specific values (e.g., month, day, mg, µg/kg).
Constraints Imposed by These Features on Multi-turn Conversations and Prompts
The highly specialized and rigorous nature of solid tumor product data demands extreme accuracy in information retrieval and generation for multi-turn conversational systems. Subtle differences in clinical efficacy data can lead to entirely different conclusions. The system must precisely identify and differentiate data under various trial conditions. Complex medical terminology and abbreviations in documents require prompt design to effectively guide the model in understanding context and avoiding semantic drift. The varying update frequencies challenge the real-time maintenance of the knowledge base, ensuring conversations are based on the latest approved information or clinical guidelines. Furthermore, consultations involving dosage and adverse events have strict safety and compliance requirements. The model needs to identify risks and provide cautious advice, avoiding misleading information. In multi-turn conversations, users may progressively inquire about a drug's performance under specific genetic mutations or classifications. This requires the system to dynamically adjust retrieval strategies and generation logic based on prior conversation content.
Configuration Guidelines
| Configuration Item | Recommended Value | Rationale |
|---|---|---|
maxContext | 8000 tokens | The solid tumor domain has specialized terminology and strong contextual relevance. A longer conversation history is needed to maintain semantic coherence. |
Chunk size (Segment Length) | 500-700 characters (characters) | Clinical reports and prescribing information have moderate paragraph lengths. This range effectively preserves semantic integrity and reduces the impact of segmentation on retrieval. |
Recall count (Number of Retrieved Items) | Top 8-12 entries (top 8-12 items) | Ensures coverage of key information from multiple relevant clinical trials or guidelines, improving answer comprehensiveness. |
Similarity threshold (Similarity Threshold) | 0.75-0.85 | Solid tumor data is highly specialized. A higher threshold ensures retrieved results are highly relevant to the user query, reducing noise. |
Rerank result count (Number of Reranked Items) | Top 5 entries (top 5 items) | After reranking, selecting the most relevant few items further improves generation quality and user experience. |
temperature | 0.3-0.5 | Solid tumor consultations require rigor and objectivity. A lower temperature reduces the probability of the model generating divergent or speculative content. |
Three Common Pitfalls
- In multi-turn conversations, the model fails to accurately distinguish data from different clinical trial phases (e.g., Phase II vs. Phase III), leading to information confusion. This happens because the knowledge base segmentation does not sufficiently retain critical metadata like trial ID and phase, leaving the model without a basis for differentiation.
- When users ask about drug adverse reactions, the system only provides general information, unable to offer detailed explanations for specific dosages or populations. This is because the adverse event data in the knowledge base lacks detailed associative information regarding specific dosages, regimens, and patient characteristics.
- Multiple AI conversation nodes are configured in a workflow, but all node outputs are directly displayed to the user, leading to information redundancy and reading burden. This occurs because the workflow lacks fine-grained control to hide or aggregate the outputs of intermediate AI conversation nodes.
How to Confirm Proper Configuration
- Select typical solid tumor drugs and simulate continuous multi-turn consultations with different focuses. Check if the answers are accurate, coherent, and effectively utilize prior conversation information.
- Randomly select solid tumor product documents from the knowledge base. Ask questions about key efficacy indicators, adverse events, and dosing regimens, then cross-reference the model's answers with the original document data for consistency.
- Ask questions related to solid tumor treatment plans associated with specific biomarkers or genetic mutations. Confirm the system can accurately identify and link to corresponding drugs or clinical trial information.
Note that the values provided are common starting points. They should be measured against your own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.